HUTCHMED (China) Business Summary

HUTCHMED (China) Ltd (HCM) operates a dual-pillar business model centered on the discovery, global clinical development, and commercialization of targeted therapies and immunotherapies for oncology and immunology. Revenue is primarily generated through three streams: direct product sales in China (e.g., ELUNATE, SULANDA, and ORPATHYS), high-margin licensing milestones and royalties from global partners such as Takeda and AstraZeneca, and a legacy prescription drug distribution business under its "Other Ventures" segment. The company has successfully transitioned from a China-centric biotech to a global commercial-stage player, notably through the international launch of fruquintinib (FRUZAQLA). Its primary business segments are Oncology/Immunology, which drives long-term value through a proprietary pipeline of over 15 clinical-stage candidates, and Other Ventures, which provides stable cash flow via pharmaceutical distribution and marketing services. Direct competitors include BeiGene, Innovent Biologics, and Zai Lab; HUTCHMED distinguishes itself through its deep R&D pedigree and a proven track record of bringing internally discovered small molecules to the global market via strategic multinational alliances. Originally founded and backed by the multinational conglomerate CK Hutchison Holdings, the company is currently led by Acting Chief Executive Officer and CFO Johnny Cheng, who has served as CFO since 2008 and brings extensive financial leadership from his prior tenure at Bristol Myers Squibb. Dr. Weiguo Su, the Chief Executive Officer and Chief Scientific Officer (currently on a leave of absence as of early 2026), is the primary architect of the company’s scientific strategy; he holds a PhD from Harvard under Nobel Laureate E.J. Corey and previously led R&D efforts at Pfizer. The executive team is further bolstered by Dr. Michael Shi, Head of R&D and Chief Medical Officer, and is overseen by Chairman Dr. Dan Eldar. Notable institutional influence is maintained through the Board of Directors, which includes Ling Yang, a Managing Director at Carlyle and Co-Head of Carlyle Asia Healthcare, reflecting the company's strong backing from major private equity and strategic investors like CK Hutchison and The Carlyle Group.